1Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci USA,2003,100:8418-8432.
2Lakhani SR,Reis-Filho JS,Fulford L,et al.Prediction of BRCA 1 status in patients with breast cancer using estrogen receptor and basal phenotype[J].Clin Cancer Res,2005,11:5175-5180.
3Foulkes WD,Stefansson IM,Chappuis PO,et al.Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer[J].J Natl Cancer Inst,2003,95:1482-1485.
4Foulkes WD,Brunet JS,Stefansson IM,et al.The prognostic implication of the basal-like phenotype of BRCA1-related breast caner[J].Cancer Res,2004,64:830-835.
5Rennert G,Bisland-Naggen S,Barnett-Griness O,et al.Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations[J].N Engl J Med,2007,357:115-123.
6Brekelmans CT,Tilanus-Linthorst MM,Seynaeve C,et al.Tumour characteristics,survival and prognostic factors of hereditary breast cancer from BRCA2-,BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases[J].Eur J Cancer,2007,43:867-876.
7Kennedy RD,Quinn JE,Mullan PB,et al.The role of BRCA1 in the cellular response to chemotherapy.J Natl Cancer Inst,2004;96:1659-68.
8Byrski T,Gronwald J,Huzarski T,et al.Response to neo-adjuvant chemotherapy in women with BRCA1 -positive breast cancers[J].Breast Cancer Res Treat,2008,108:289-296.
9Byrski T,Huzarski T,Dent R,et al.Response to neoadjuvant therapy with cisplatin in BRCA1 -positive breast cancer patients[J].Breast Cancer Res Treat,2009,115:359-363.
10Gronwald J,Byrski T,Huzarski T,et al.Neoadjuvant therapy with cisplatin in BRCA 1-positive breast cancer patients[J].Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology,Orlando,Florida (Abstract 502).
